{"url_path":"/sec/ipsc/8-k/2026-06-16/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-074577-index.html","accession_number":"0001104659-26-074577","cik":"0001850119","ticker":"IPSC","issuer_name":"Century Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-074577-index.html","primary_entity_key":"0001850119","primary_entity_name":"Century Therapeutics, Inc."},"word_count":554,"has_tables":true,"body_markdown":"false\n0001850119\n\n0001850119\n\n2026-06-15\n2026-06-15\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n \n\n \n\n** **\n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nJune 15, 2026**\n\n \n\n \n\n \n\n**Century Therapeutics, Inc.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n \n\n \n\n**Delaware**\n \n**001-40498**\n \n**84-2040295**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n \n(Commission File Number)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**25\nNorth 38th Street**, **11th Floor**\n\n**Philadelphia, Pennsylvania**\n\n \n**19104**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(267) 817-5790**\n\n \n\n**Not Applicable**\n\n(Former name or former address, if changed since\nlast report)\n\n \n\n \n\n** **\n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.\nbelow):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n \n**Trading Symbol**\n \n**Name\nof Exchange on Which Registered**\n\n**Common Stock, par value $0.0001 per share**\n \n**IPSC**\n \n**Nasdaq Capital Market**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨\n\n \n\n \n\n \n\n \n\n \n\nI**tem 5.02    Departure\nof Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 15, 2026,\nCentury Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “A&R\nAgreement”) with Chad Cowan, Ph.D., the Company’s Chief Scientific Officer. Pursuant to the A&R Agreement, Dr. Cowan\nwill continue as the Company’s Chief Scientific Officer on a part-time basis, at a reduced annual salary of $296,150 and will be\neligible for an annual performance-based target bonus on a pro-rated basis. In the event of termination of Dr. Cowan’s employment\nby the Company or Dr. Cowan’s resignation from the Company, Dr. Cowan will be entitled to all accrued and unpaid base\nsalary through the date of cessation of his employment.\n\n \n\nThe foregoing description\nof the A&R Agreement does not purport to be complete and is qualified in its entirety by reference to the A&R Agreement, which will be\nfiled as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**CENTURY THERAPEUTICS, INC.**\n\n \n \n \n\n \nBy:\n/s/ Brent Pfeiffenberger, Pharm.D., M.B.A.\n\n \nName:\nBrent Pfeiffenberger, Pharm.D., M.B.A.\n\n \nTitle:\nPresident, Chief Executive Officer and Chairman of the Board of Directors\n\n \n\nDate: June 16, 2026"}